114 related articles for article (PubMed ID: 8382855)
1. Comparative effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine treatment on cytomegalovirus-induced interstitial pneumonitis in allogeneic bone marrow transplant recipient rats.
Stals FS; Zeytinoglu A; Havennith M; de Clercq E; Bruggeman CA
Transplant Proc; 1993 Feb; 25(1 Pt 2):1248-9. PubMed ID: 8382855
[No Abstract] [Full Text] [Related]
2. Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Stals FS; Zeytinoglu A; Havenith M; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1993 Feb; 37(2):218-23. PubMed ID: 8383939
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
Neyts J; Balzarini J; Naesens L; De Clercq E
J Med Virol; 1992 May; 37(1):67-71. PubMed ID: 1320099
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of experimental cytomegalovirus-induced encephalo-meningitis in immunocompromised rats with HPMPC.
Kloover JS; Vanagt WY; Stals FS; Bruggeman CA
Antiviral Res; 1997 Jul; 35(2):105-12. PubMed ID: 9217247
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
Seo SK; Regan A; Cihlar T; Lin DC; Boulad F; George D; Prasad VK; Kiehn TE; Polsky B
Clin Infect Dis; 2001 Nov; 33(9):e105-8. PubMed ID: 11577375
[TBL] [Abstract][Full Text] [Related]
6. Failure of cidofovir to reduce CMV-antigenemia in a child transplanted from a matched unrelated donor.
Castagnola E; Cristina E; Dallorso S; Lanino E; Giacchino R
J Chemother; 2001 Feb; 13(1):100-1. PubMed ID: 11233794
[No Abstract] [Full Text] [Related]
7. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Stals FS; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
Neyts J; Sobis H; Snoeck R; Vandeputte M; De Clercq E
Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):269-79. PubMed ID: 8390357
[TBL] [Abstract][Full Text] [Related]
9. Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Castagnola E; Miano M; Morreale G; Cristina E; Chierici M; Lanino E
Blood; 2001 Sep; 98(5):1627-8; author reply 1628-9. PubMed ID: 11547769
[No Abstract] [Full Text] [Related]
10. Cytomegalovirus: disease syndromes and treatment.
Drew WL; Lalezari JP
Curr Clin Top Infect Dis; 1999; 19():16-29. PubMed ID: 10472478
[No Abstract] [Full Text] [Related]
11. New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Cunningham ET
West J Med; 1997 Feb; 166(2):138-9. PubMed ID: 9109331
[No Abstract] [Full Text] [Related]
12. Value of animal models to evaluate agents with potential activity against human cytomegalovirus.
Kern ER
Transplant Proc; 1991 Jun; 23(3 Suppl 3):152-5, discussion 155. PubMed ID: 1648821
[No Abstract] [Full Text] [Related]
13. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Kiehl MG; Basara N
Blood; 2001 Sep; 98(5):1626; author reply 1628. PubMed ID: 11547768
[No Abstract] [Full Text] [Related]
14. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
15. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G
Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806
[TBL] [Abstract][Full Text] [Related]
16. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
Zaia JA
Bone Marrow Transplant; 2002 Apr; 29(8):633-8. PubMed ID: 12180106
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus drug resistance.
Emery VC
Antivir Ther; 1998; 3(4):239-42. PubMed ID: 10682146
[TBL] [Abstract][Full Text] [Related]
18. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir.
Held TK; Biel SS; Nitsche A; Kurth A; Chen S; Gelderblom HR; Siegert W
Bone Marrow Transplant; 2000 Aug; 26(3):347-50. PubMed ID: 10967578
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC.
Bruning JH; Persoons M; Lemström K; Stals FS; De Clercq E; Bruggeman CA
Transpl Int; 1994; 7 Suppl 1():S365-70. PubMed ID: 11271253
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection in patients with HIV infection.
Cheung TW; Teich SA
Mt Sinai J Med; 1999 Mar; 66(2):113-24. PubMed ID: 10100416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
